2682 related articles for article (PubMed ID: 23954314)
1. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
Ferrante M; Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens GR; van der Woude CJ; Danese S; Diamond RH; Oortwijn AF; Tang KL; Miller M; Cornillie F; Rutgeerts PJ;
Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314
[TBL] [Abstract][Full Text] [Related]
2. Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn's disease.
Ordás I; Rimola J; Rodríguez S; Paredes JM; Martínez-Pérez MJ; Blanc E; Arévalo JA; Aduna M; Andreu M; Radosevic A; Ramírez-Morros AM; Pinó S; Gallego M; Jauregui-Amezaga A; Ricart E; Panés J
Gastroenterology; 2014 Feb; 146(2):374-82.e1. PubMed ID: 24177375
[TBL] [Abstract][Full Text] [Related]
3. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial.
Peyrin-Biroulet L; Reinisch W; Colombel JF; Mantzaris GJ; Kornbluth A; Diamond R; Rutgeerts P; Tang LK; Cornillie FJ; Sandborn WJ
Gut; 2014 Jan; 63(1):88-95. PubMed ID: 23974954
[TBL] [Abstract][Full Text] [Related]
4. Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis.
Colombel JF; Reinisch W; Mantzaris GJ; Kornbluth A; Rutgeerts P; Tang KL; Oortwijn A; Bevelander GS; Cornillie FJ; Sandborn WJ
Aliment Pharmacol Ther; 2015 Apr; 41(8):734-46. PubMed ID: 25728587
[TBL] [Abstract][Full Text] [Related]
5. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease.
Baert F; Moortgat L; Van Assche G; Caenepeel P; Vergauwe P; De Vos M; Stokkers P; Hommes D; Rutgeerts P; Vermeire S; D'Haens G; ;
Gastroenterology; 2010 Feb; 138(2):463-8; quiz e10-1. PubMed ID: 19818785
[TBL] [Abstract][Full Text] [Related]
6. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease.
af Björkesten CG; Nieminen U; Sipponen T; Turunen U; Arkkila P; Färkkilä M
Scand J Gastroenterol; 2013 May; 48(5):543-51. PubMed ID: 23477356
[TBL] [Abstract][Full Text] [Related]
7. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease.
Rutgeerts P; Diamond RH; Bala M; Olson A; Lichtenstein GR; Bao W; Patel K; Wolf DC; Safdi M; Colombel JF; Lashner B; Hanauer SB
Gastrointest Endosc; 2006 Mar; 63(3):433-42; quiz 464. PubMed ID: 16500392
[TBL] [Abstract][Full Text] [Related]
8. Endoscopic response to tumor necrosis factor inhibitors predicts long term benefits in Crohn's disease.
Alfaro I; Masamunt MC; Planell N; López-García A; Castro J; Gallego M; Barastegui R; Giner A; Vara A; Salas A; Ricart E; Panés J; Ordás I
World J Gastroenterol; 2019 Apr; 25(14):1764-1774. PubMed ID: 31011260
[TBL] [Abstract][Full Text] [Related]
9. Mucosal healing of ileal lesions is associated with long-term clinical remission after infliximab maintenance treatment in patients with Crohn's disease.
Beppu T; Ono Y; Matsui T; Hirai F; Yano Y; Takatsu N; Ninomiya K; Tsurumi K; Sato Y; Takahashi H; Ookado Y; Koga A; Kinjo K; Nagahama T; Hisabe T; Takaki Y; Yao K
Dig Endosc; 2015 Jan; 27(1):73-81. PubMed ID: 24833527
[TBL] [Abstract][Full Text] [Related]
10. Factors associated with short- and long-term outcomes of therapy for Crohn's disease.
Reinisch W; Colombel JF; Sandborn WJ; Mantzaris GJ; Kornbluth A; Adedokun OJ; Miller M; Tang KL; Rutgeerts P; Cornillie F
Clin Gastroenterol Hepatol; 2015 Mar; 13(3):539-547.e2. PubMed ID: 25245629
[TBL] [Abstract][Full Text] [Related]
11. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease.
af Björkesten CG; Nieminen U; Turunen U; Arkkila P; Sipponen T; Färkkilä M
Scand J Gastroenterol; 2012 May; 47(5):528-37. PubMed ID: 22356594
[TBL] [Abstract][Full Text] [Related]
12. Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease.
Danese S; Sandborn WJ; Colombel JF; Vermeire S; Glover SC; Rimola J; Siegelman J; Jones S; Bornstein JD; Feagan BG
Gastroenterology; 2019 Oct; 157(4):1007-1018.e7. PubMed ID: 31279871
[TBL] [Abstract][Full Text] [Related]
13. Endoscopic scoring indices for evaluation of disease activity in Crohn's disease.
Khanna R; Nelson SA; Feagan BG; D'Haens G; Sandborn WJ; Zou GY; MacDonald JK; Parker CE; Jairath V; Levesque BG
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD010642. PubMed ID: 27501379
[TBL] [Abstract][Full Text] [Related]
14. The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's disease.
Kierkus J; Dadalski M; Szymanska E; Oracz G; Wegner A; Gorczewska M; Szymanska S; Woynarowski M; Ryzko J
Eur J Gastroenterol Hepatol; 2012 May; 24(5):495-500. PubMed ID: 22387887
[TBL] [Abstract][Full Text] [Related]
15. Definition and evaluation of mucosal healing in clinical practice.
Mazzuoli S; Guglielmi FW; Antonelli E; Salemme M; Bassotti G; Villanacci V
Dig Liver Dis; 2013 Dec; 45(12):969-77. PubMed ID: 23932331
[TBL] [Abstract][Full Text] [Related]
16. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
17. Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease.
Löwenberg M; Vermeire S; Mostafavi N; Hoentjen F; Franchimont D; Bossuyt P; Hindryckx P; Rispens T; de Vries A; van der Woude CJ; Berends S; Ambarus CA; Mathot R; Clasquin E; Baert F; D'Haens G
Gastroenterology; 2019 Oct; 157(4):997-1006.e6. PubMed ID: 31175865
[TBL] [Abstract][Full Text] [Related]
18. Responsiveness of Endoscopic Indices of Disease Activity for Crohn's Disease.
Khanna R; Zou G; Stitt L; Feagan BG; Sandborn WJ; Rutgeerts P; McDonald JWD; Dubcenco E; Fogel R; Panaccione R; Jairath V; Nelson S; Shackelton LM; Huang B; Zhou Q; Robinson AM; Levesque BG; D'Haens G
Am J Gastroenterol; 2017 Oct; 112(10):1584-1592. PubMed ID: 28071654
[TBL] [Abstract][Full Text] [Related]
19. A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy.
Forbes GM; Sturm MJ; Leong RW; Sparrow MP; Segarajasingam D; Cummins AG; Phillips M; Herrmann RP
Clin Gastroenterol Hepatol; 2014 Jan; 12(1):64-71. PubMed ID: 23872668
[TBL] [Abstract][Full Text] [Related]
20. Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial.
Rutgeerts P; Reinisch W; Colombel JF; Sandborn WJ; D'Haens G; Petersson J; Zhou Q; Iezzi A; Thakkar RB
Gastrointest Endosc; 2016 Jan; 83(1):188-97.e1-3. PubMed ID: 26234693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]